MedTrace Logo

Naltrexone in the Treatment of Trichotillomania

NCT00775229 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2023-02-23

Study results available
· View outcomes & findings →

Summary

This is an 8-week, double-blind study of Natrexone in the treatment of trichotillomania

Conditions

  • Trichotillomania

Interventions

DRUG

Naltrexone

pill, by mouth, 50mg-150mg/day for the duration of the study

DRUG

Placebo

pill, by mouth, daily

Sponsors & Collaborators

  • University of Chicago

    lead OTHER

Principal Investigators

  • Jon E Grant, M.D. · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2012-11-30
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00775229 on ClinicalTrials.gov